Enhanced absorption of nasulin™, an ultrarapid-acting intranasal insulin formulation, using single nostril administration in normal subjects

Journal of Diabetes Science and Technology

Volumn 5, Issue 1, 2011, Pages 113-119

  Stote, Robert ^a   Miller, Michael ^b   Marbury, Thomas ^c   Shi, Leon ^b   Strange, Poul ^b  

^a CPEX Pharmaceuticals Inc   (United States)

^b Integrated Medical Development   (United States)

^c ORLANDO CLINICAL RESEARCH CENTER   (United States)

Author keywords

CPE 215; Cyclopentadecalactone; Intranasal insulin; Nasulin; Ultrarapid time action profile

Indexed keywords

CYCLOPENTADECALACTONE; EXCIPIENT; INSULIN; NASULIN; NOSE SPRAY; PLACEBO; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE METER; BODY MASS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG INDUCED HEADACHE; DYSGEUSIA; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; LACRIMATION; MAXIMUM PLASMA CONCENTRATION; MEAL; NORMAL HUMAN; NOSE IRRITATION; NOSE OBSTRUCTION; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; REPEATED DRUG DOSE; SIDE EFFECT; SNEEZING; THROAT IRRITATION; TIME TO MAXIMUM PLASMA CONCENTRATION; ABSORPTION; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; FEASIBILITY STUDY; HEALTH; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; NOSE; RANDOMIZED CONTROLLED TRIAL; TIME;

ABSORPTION; ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEASIBILITY STUDIES; HEALTH; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; NASAL SPRAYS; NOSE; PLACEBOS; TIME FACTORS; YOUNG ADULT;

EID: 79958015348     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681100500116     Document Type: Article

References (6)

1. Schwartz S, Ryan T, Stote R. Results of a randomized, single-dose, 2/3-way crossover comparison study of intranasal insulin spray (NasulinTM) injectable fast-acting insulin (Humalog®) in normal nonsmoking and smoking subjects. Diabetes. 2007;56(Suppl 1A):02-LB.
2. Leary AC, Dowling M, Cussen K, O'Brien J, Stote RM. Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: influence of the nasal cycle. J Diabetes Sci Technol. 2008;2(6):1054-60.
3. Stote R, Schwartz S, Dehn C, Strange P. Two randomized crossover glucose clamp studies of NasulinTM and lispro SC. Poster, Diabetes Technology Meeting. November, 2009.
4. Stote R, Marbury T, Shi L, Miller M, Strange P. Comparison pharmacokinetics of two concentrations (0.7% and 1.0%) of Nasulin, an ultra-rapid-acting intranasal insulin formulation. J Diabetes Sci Technol. 2010;4(3):603-9.
5. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care. 1984;7(2):188-99.
6. Heinemann L. Time-action profiles of insulin preparations. Mainz, Germany: Kirchheim & Co GmbH; 2004.